CSPC Pharmaceutical GroupCSPCY +4.25%74 ROC (Joel Greenblatt) % is 14.59% as of Dec. 2025, which is 73% below its 10-year median of 54.81. GuruFocus rates CSPCY with a GF Scoreâ„¢ of 74/100 and a GF Valueâ„¢ of $3.41 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 978 Drug Manufacturers companies, CSPC Pharmaceutical Group ranks better than 75.46% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CSPC Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 14.59%.
The historical rank and industry rank for CSPC Pharmaceutical Group's ROC (Joel Greenblatt) % or its related term are showing as below:
CSPCY'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 31.32 Med: 54.81 Max: 71.13
Current: 31.32
During the past 13 years, CSPC Pharmaceutical Group's highest ROC (Joel Greenblatt) % was 71.13%. The lowest was 31.32%. And the median was 54.81%.
CSPCY's ROC (Joel Greenblatt) % is ranked better than 75.46% of 978
companies
in the Drug Manufacturers industry
Industry Median: 11.495
vs CSPCY: 31.32
CSPC Pharmaceutical Group's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -12.70% per year.
CSPC Pharmaceutical Group (OTCPK:CSPCY) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
CSPC Pharmaceutical Group ROC (Joel Greenblatt) % Related Terms
CSPC Pharmaceutical Group ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for CSPC Pharmaceutical Group's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSPC Pharmaceutical Group ROC (Joel Greenblatt) % Chart
CSPCY vs LLY, JNJ, ABBV: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSPC Pharmaceutical Group ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where CSPC Pharmaceutical Group's ROC (Joel Greenblatt) % falls into.
CSPC Pharmaceutical Group ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 14.59% mean?
CSPC Pharmaceutical Group (CSPCY) has a ROC (Joel Greenblatt) % of 14.59% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CSPC Pharmaceutical Group and its competitors. This is 73% below median its historical median of 54.81. Over the past decade, CSPC Pharmaceutical Group's ROC (Joel Greenblatt) % has ranged from 31.32 to 71.13. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #240 out of 978 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is CSPC Pharmaceutical Group's ROC (Joel Greenblatt) % too high?
CSPC Pharmaceutical Group's current ROC (Joel Greenblatt) % of 14.59% is 73% below median its 10-year median of 54.81. Over the past 10 years, this metric has ranged from a low of 31.32 to a high of 71.13. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.50. CSPC Pharmaceutical Group's value of 14.59% is 26.9% above this industry median. Based on the distribution chart, CSPC Pharmaceutical Group ranks #240 out of 978 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, CSPC Pharmaceutical Group has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's ROC (Joel Greenblatt) % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #240 out of 978 companies for ROC (Joel Greenblatt) %. This places CSPC Pharmaceutical Group in the top 25% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.50. CSPC Pharmaceutical Group's value of 14.59% is 26.9% above this benchmark. Historically, CSPC Pharmaceutical Group's own ROC (Joel Greenblatt) % has ranged from 31.32 to 71.13 over the past decade. While the company's 10-year median is 54.81 vs. the industry median of 11.50, CSPC Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.50, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSPC Pharmaceutical Group's current ROC (Joel Greenblatt) % of 14.59% is 26.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CSPC Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSPC Pharmaceutical Group's current ROC (Joel Greenblatt) % is 14.59%, which is 73% below median its own 10-year median of 54.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (CSPCY) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.41, compared to a current price of $4.17 — trading 22.3% above its estimated fair value. The current ROC (Joel Greenblatt) % is 14.59%, which is 73% below median its 10-year median of 54.81 and 26.9% above the Drug Manufacturers industry median of 11.50. CSPC Pharmaceutical Group's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For CSPC Pharmaceutical Group (CSPCY), the current ROC (Joel Greenblatt) % is 14.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSPC Pharmaceutical Group (CSPCY) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of $4.17 is trading 22.3% above its estimated GF Value™ of $3.41.
GuruFocus considers CSPC Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for CSPCY:
ROC (Joel Greenblatt) %: 14.59% (73% below median its 10-year median of 54.81)
GF Value™: $3.41 vs. price of $4.17 (22.3% above fair value)
Industry Position: 26.9% above the Drug Manufacturers median (#240 of 978)
No single metric tells the full story. See the CSPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
74GF Score
Get the complete analysis for CSPCY
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSPCY has been successfully added to your 
